What is the official website of Zoetis ?

The official website of Zoetis is http://www.zoetis.com.

What is Zoetis's cybersecurity risk score?

Zoetis has an AI-generated cybersecurity risk score of 802 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Zoetis experienced?

According to Rankiteo, Zoetis currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Zoetis been affected by any supply chain cyber incidents ?

According to Rankiteo, Zoetis has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Zoetis have SOC 2 Type 1 certification ?

According to Rankiteo, Zoetis is not certified under SOC 2 Type 1.

Does Zoetis have SOC 2 Type 2 certification ?

According to Rankiteo, Zoetis does not hold a SOC 2 Type 2 certification.

Does Zoetis comply with GDPR ?

According to Rankiteo, Zoetis is not listed as GDPR compliant.

Does Zoetis have PCI DSS certification ?

According to Rankiteo, Zoetis does not currently maintain PCI DSS compliance.

Does Zoetis comply with HIPAA ?

According to Rankiteo, Zoetis is not compliant with HIPAA regulations.

Does Zoetis have ISO 27001 certification ?

According to Rankiteo,Zoetis is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Zoetis operate in ?

Zoetis operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Zoetis have ?

Zoetis employs approximately 12,134 people worldwide.

Does Zoetis own any subsidiaries ?

Zoetis presently has no subsidiaries across any sectors.

How many LinkedIn followers does Zoetis have ?

Zoetis's official LinkedIn profile has approximately 576,885 followers.

What is the NAICS classification code for Zoetis ?

Zoetis is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Zoetis have a Crunchbase profile ?

No, Zoetis does not have a profile on Crunchbase.

Does Zoetis have a LinkedIn profile ?

Yes, Zoetis maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/zoetis.

How many cybersecurity incidents has Zoetis experienced ?

As of September 27, 2026, Rankiteo reports that Zoetis has not experienced any cybersecurity incidents.

How many peer or competitor companies does Zoetis have ?

Zoetis has an estimated 5,769 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Zoetis

Boost Score +25 with badge (5 left)

802

/1000

Good

827

/1000

Good

Zoetis Vendor Cyber Rating & Cyber Score

zoetis.com

Add Your Compliance Badge

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call

Zoetis

Zoetis CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Zoetis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Zoetis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Zoetis in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Zoetis in 2026.

Incident Types Zoetis vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Zoetis in 2026.

Incident History - Zoetis (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Zoetis Subsidiaries

Parent Company

Zoetis

Pharmaceutical Manufacturing

Website: http://www.zoetis.com

Company Size: 10,000+ employees

No subsidiary data available for this company.

Loading…

Zoetis Similar Companies

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, with 140 years of history, present in 140 countries worldwide, with a turnover of 4.88 billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants and is distributed across six continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Servier

servier.com

Servier is an independent international pharmaceutical group governed by a foundation. With its unique governance model, the Group is committed to therapeutic progress to serve patients and integrates the patient voice at every stage of the medicine life cycle. As a leading global player in cardiology and venous diseases, Servier aims to become a leading innovator in oncology and neurology. Through precision medicine, the Group intends to offer targeted therapeutic solutions for a limited number of rare diseases and invests nearly 20% of its brand-name sales in R&D. Headquartered in France, Servier relies on its more than 20,000 employees and a solid geographic presence with medicines distributed in more than 130 countries. In the 2024/25 financial year, the Group achieved revenues of €6.9 billion. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Loading…

NEWS

Zoetis CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

April 03, 2026 06:59 AM

Zscaler Stock After Earnings: Can This Cyber Name Keep Outgrowing the Nasdaq?

Zscaler just dropped fresh earnings and guidance that jolted the cyber trade, but the market reaction was anything but simple.

Read Article

October 01, 2025 07:00 AM

Cybersecurity Awareness Month: Oklahoma’s commitment to a safer digital future

In a joint effort with the Office of Management and Enterprise Services (OMES), Gov. J. Kevin Stitt has declared October 2025 as...

Read Article

October 01, 2025 07:00 AM

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Zoetis announced today that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the...

Read Article

September 19, 2025 07:00 AM

Tata Communications Limited lauded at Asian Technology Excellence Awards 2025 for SIEM-led transformation

Cyber resilience transformation with Kotak Mahindra Asset Management Company earns recognition.

Read Article

June 27, 2025 07:00 AM

Animal health company Zoetis signs consulting deal with Infosys

Infosys, an India-based IT consulting firm, has won a consulting contract with Zoetis, an American drug company focusing on pets and livestock.

Read Article

April 23, 2025 07:00 AM

Infosys buys Australian IT consultancy The Missing Link for $98 million

Global technology consultancy Infosys has forked out almost $100 million for Sydney-headquartered cyber solutions and consulting firm The...

Read Article

March 21, 2025 07:00 AM

PNB brings home top honours at Malaysia Technology Excellence Awards 2025

Programme HIMAYA highlights the group's commitment to maintaining robust cybersecurity measures and protecting investors and stakeholders.

Read Article

March 07, 2024 08:00 AM

Thailand cybersecurity job market sees 15% growth in 10 years

The cybersecurity job market in Thailand is expected to see a robust growth of 15% over the next decade, hence the need for specialized skills.

Read Article

July 21, 2023 07:00 AM

Zoetis IT Leader Wafaa Mamilli: ‘Play Offense’

Wafaa Mamilli holds an array of impressive titles at Fortune 500 animal health company Zoetis, including executive vice president, chief digital and technology...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-100739

SUMMARY

A vulnerability was detected in mathurvishal CloudClassroom-PHP-Project up to 5dadec098bfbbf3300d60c3494db3fb95b66e7be. This impacts an unknown function of the file viewresult.php. Performing a manipulation of the argument seno results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used. This product follows a rolling release approach for continuous delivery, so version details for affected or updated releases are not provided. The vendor was contacted early about this disclosure but did not respond in any way.

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-94408

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Elasticsearch can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 4.9)

cvss3

Base Score: 4.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

1.2

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-22-9-4-7-9-5-3-security-update-esa-2026-184/390688

CVE-2026-94400

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Kibana can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/kibana-8-19-22-9-4-7-9-5-3-security-update-esa-2026-181/390685

CVE-2026-94399

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Elasticsearch can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-22-9-4-7-9-5-4-security-update-esa-2026-180/390684

CVE-2026-94398

SUMMARY

Uncontrolled Resource Consumption (CWE-400) in Elasticsearch can lead denial of service via Excessive Allocation (CAPEC-130)

Published

Date2026-09-26

Updated

Date2026-09-26

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.8

REFERENCES

https://discuss.elastic.co/t/elasticsearch-8-19-22-9-4-7-9-5-4-security-update-esa-2026-179/390683

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Zoetis Vendor Cyber Rating & Cyber Score

Zoetis A.I CyberSecurity Scoring

Zoetis CyberSecurity News & History

Zoetis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Zoetis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Zoetis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Zoetis (X = Date, Y = Severity)

Zoetis Subsidiaries

Parent Company

Zoetis

Zoetis Similar Companies

MENARINI Group

Bristol Myers Squibb

Servier

Lupin

MACLEODS PHARMACEUTICALS LTD.

Dr. Reddy's Laboratories

Teva Pharmaceuticals

Sandoz

Hikma Pharmaceuticals

Zoetis CyberSecurity News

Zscaler Stock After Earnings: Can This Cyber Name Keep Outgrowing the Nasdaq?

Cybersecurity Awareness Month: Oklahoma’s commitment to a safer digital future

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Tata Communications Limited lauded at Asian Technology Excellence Awards 2025 for SIEM-led transformation

Animal health company Zoetis signs consulting deal with Infosys

Infosys buys Australian IT consultancy The Missing Link for $98 million

PNB brings home top honours at Malaysia Technology Excellence Awards 2025

Thailand cybersecurity job market sees 15% growth in 10 years

Zoetis IT Leader Wafaa Mamilli: ‘Play Offense’

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Zoetis CyberSecurity News & History

Zoetis Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Zoetis

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Zoetis vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Zoetis (X = Date, Y = Severity)

Zoetis Subsidiaries

Parent Company

Zoetis

Zoetis Similar Companies

MENARINI Group

Bristol Myers Squibb

Servier

Lupin

MACLEODS PHARMACEUTICALS LTD.

Dr. Reddy's Laboratories

Teva Pharmaceuticals

Sandoz

Hikma Pharmaceuticals

Zoetis CyberSecurity News

Zscaler Stock After Earnings: Can This Cyber Name Keep Outgrowing the Nasdaq?

Cybersecurity Awareness Month: Oklahoma’s commitment to a safer digital future

Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle

Tata Communications Limited lauded at Asian Technology Excellence Awards 2025 for SIEM-led transformation

Animal health company Zoetis signs consulting deal with Infosys

Infosys buys Australian IT consultancy The Missing Link for $98 million

PNB brings home top honours at Malaysia Technology Excellence Awards 2025

Thailand cybersecurity job market sees 15% growth in 10 years

Zoetis IT Leader Wafaa Mamilli: ‘Play Offense’

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?